Form 4: Insider Boosts Cocrystal Pharma Stake

Phillip Frost, a Director and 10% owner of Cocrystal Pharma, Inc., acquired 50,000 shares of common stock at a weighted average price of $0.9455.

Summary

• Phillip Frost, MD, a Director and 10% owner of Cocrystal Pharma, Inc. (COCP), acquired 50,000 shares of common stock.
• The transaction occurred on December 31, 2025, at a weighted average price of $0.9455 per share.
• The shares were acquired in multiple transactions with prices ranging from $0.9370 to $0.9519.
• Following this acquisition, Frost's indirect beneficial ownership through Frost Gamma Investments Trust is 1,838,551 shares.
• Additionally, Frost directly owns 27,100 shares, which includes shares issuable upon vesting of restricted stock units.
• The total beneficial ownership reported by Frost is 1,865,651 shares.
• Frost disclaims beneficial ownership of securities held by OPKO Health, Inc., where he is Chairman and CEO, as he does not hold voting and investment control over those shares.

Sentiment

Score: 7

Explanation: The acquisition of shares by a significant insider (Director and 10% owner) generally indicates a positive sentiment towards the company's future prospects, suggesting confidence in its valuation or strategic direction.

Positives

• A key insider, Phillip Frost (Director and 10% owner), increased his stake in Cocrystal Pharma, indicating confidence in the company's future prospects.
• The acquisition of 50,000 shares demonstrates a direct investment by a significant stakeholder at a weighted average price of $0.9455 per share.

Negatives

• None directly identifiable from this insider transaction report.

Risks

• This filing is a transaction report and does not detail company-specific operational or financial risks.

Future Outlook

This Form 4 filing is a transaction report and does not contain specific forward-looking statements or guidance regarding the company's future operations or financial performance.

Management Comments

• The reporting person undertakes to provide to Cocrystal Pharma, Inc., any security holder of Cocrystal Pharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the ranges set forth in the preceding sentence.
• The Reporting Person disclaims beneficial ownership of the securities held by Frost Gamma Investments Trust except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
• This Form 4 does not include any of the securities owned directly by OPKO Health, Inc., a company of which Dr. Frost is the Chairman of the Board and Chief Executive Officer, concerning the securities of which Dr. Frost does not hold voting and investment control. Dr. Frost disclaims beneficial ownership of the securities held by OPKO Health, Inc. except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.

Industry Context

This insider transaction reflects an individual's investment decision within the biotechnology/pharmaceutical sector. Without further context on Cocrystal Pharma's specific drug development pipeline or market position, it is difficult to draw broader industry conclusions from this single transaction. However, insider buying can sometimes signal confidence in a company's prospects within its competitive landscape.

Comparison to Industry Standards

• This filing reports an insider stock acquisition and does not provide data for comparison to industry-specific operational or financial benchmarks. The transaction is a standard insider purchase, common across all industries.

Related Party Transactions

• Acquisition of 50,000 common shares by Phillip Frost, a Director and 10% owner, from the open market at a weighted average price of $0.9455.

Stakeholder Impact

• Shareholders: The acquisition by a significant insider could be viewed positively, potentially boosting investor confidence and signaling a belief in future stock appreciation.
• Management/Employees: May interpret the insider purchase as a sign of stability and confidence from a key board member and owner.

Next Steps

• The filing does not specify any future actions, events, or milestones for the company or the reporting person beyond the transaction itself.

Key Dates

Recommendation

The acquisition of 50,000 shares by a Director and 10% owner, Phillip Frost, at a weighted average price of $0.9455, signals insider confidence in Cocrystal Pharma, Inc. While this is a positive indicator, a Form 4 filing primarily reports a transaction and does not provide comprehensive financial or operational details to warrant a 'buy' or 'sell' recommendation. For existing shareholders, this transaction reinforces a 'hold' position, suggesting that a key insider sees value at current levels. New investors should conduct further due diligence beyond this transaction report.

Keywords

Cocrystal Pharma, COCP, Phillip Frost, Insider Trading, Form 4, Stock Acquisition, Beneficial Ownership, Director, 10% Owner, Biotechnology, Pharmaceuticals